The Medicines Company Wins US Patent For Angiomax

The Medicines Company has reported that the US Patent and Trademark Office (PTO) issued a new US patent No 7582727 (‘727 patent). The ‘727 patent relates to a more consistent and improved Angiomax drug product.

Reportedly, the new patent has been submitted to the FDA for listing in the FDA’s publication Approved Drug Products with Therapeutic Equivalence Evaluations, which is commonly known as the Orange Book, for Angiomax.

The company said that Angiomax is already protected under US patent No. 5196404 (‘404 patent), which covers the composition of matter of bivalirudin. The ‘404 patent expires on March 23, 2010. Additionally, Angiomax has been awarded pediatric exclusivity, which expires on September 23, 2010.